Browse our 650+ Publications​

Latest Publications

Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis

Kawano Y, et al.
Clinical Lymphoma Myeloma & Leukemia
July 2023
Authors and Affiliates
Yawara Kawano1, Kihyun Kim2, Chang Ki Min3, Youngil Koh4, Kenichi Ishizawa5, Sung Hyun Kim6, Shigeki Ito7, Junji Tanaka8, Michihiro Uchiyama9, Tadao Ishida10, Jin Seok Kim11, Philippe Moreau12, Thomas Martin13, Keisuke Tada14, Marie-Laure Risse15, Kenshi Suzuki16 1Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan;2Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea;3Department of Hematology, Seoul St Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea;4Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea;5Department of Hematology and Cell Therapy, Yamagata University, Yamagata, Japan;6Department of Internal Medicine, Dong-A University College of Medicine, Busan, Republic of Korea;7Division of Hematology & Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Japan;8Department of Hematology, Tokyo Women’s Medical University, Tokyo, Japan;9Department of Hematology, Japanese Red Cross Society, Suwa Hospital, Suwa, Japan;10Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan;11Department of Hematology, Severance Hospital, Seoul, Republic of Korea;12Department of Hematology, University Hospital of Nantes, 44093 Nantes, France;13Department of Medicine, University of California, San Francisco, CA;14Research and Development, Sanofi K.K., Tokyo, Japan;15Sanofi Research and Development, Vitry-sur-Seine, France;16Myeloma/Amyloidosis Center, Japanese Red Cross Medical Center, Tokyo, Japan

Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation.

Ocio EM, et al.
Leukemia
June 2023
Authors and Affiliates
Enrique M. Ocio 1, Aurore Perrot 2, Pierre Bories3, Jesus F. San-Miguel 4, Igor W. Blau5, Lionel Karlin6, Joaquin Martinez-Lopez7,Song-Yau Wang8, Sara Bringhen 9, Magda Marcatti10, María-Victoria Mateos 11, Paula Rodriguez-Otero 4, Stefania Oliva 12,Axel Nogai5, Nadia Le Roux13, Liyan Dong14, Sandrine Macé15, Matthieu Gassiot16, Thomas Fitzmaurice17, Corina Oprea18 and Philippe Moreau 1 1University Hospital Marqués de Valdecilla (IDIVAL), University of Cantabria, Santander, Spain. 2CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’Hématologie,Toulouse, France. 3Toulouse University Institute of Cancer-Oncopole, Toulouse, France. 4Clinica Universidad de Navarra, CCUN, CIMA, IDISNA, CIBERONC, Pamplona, Spain. 5Charité Medical University, Berlin, Germany. 6Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France. 7Hospital 12 de Octubre, Complutense University, CNIO, Madrid, Spain. 8Department of Hematology and Oncology, University of Leipzig, Leipzig, Germany. 9SSD Clinical Trial in Oncoematologia e Mieloma Multiplo, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy. 10Vita-Salute San Raffaele University, Milan, Italy. 11University Hospital of Salamanca, IBSAL, CSIC/CIC, Salamanca, Spain. 12Dipartimento di Oncologia ed Ematologia SC Ematologia 1 U, Torino, Italy. 13Sanofi Research & Development on behalf of Altran, Vitry-sur-Seine, France. 14Sanofi, Beijing, China. 15Sanofi Translational Medicine, Chilly-Mazarin, France. 16Sanofi Research & Development on behalf of Excelya, Montpellier, France. 17Sanofi, Cambridge, MA, USA. 18Sanofi Oncology, Vitry-sur-Seine, France. 19University of Nantes, Nantes, France.

Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing

Oliva S, et al.
The Lancet
June 2023
Authors and Affiliates
Stefania Oliva,a Elisa Genuardi,b Laura Paris,c Mattia D’Agostino,a,b Jennifer Rogers,d Delia Rota-Scalabrini,e Allison P. Jacob,f Francesca Patriarca,gMario Luppi,h Paola Bertazzoni,i Cristina Velluti,b Andrea Capra,b Elona Saraci,b Marco Rossi,j Alessandro Allegra,k Roberto Mina,a,b Massimo Gentile,l Ilan R. Kirsch,f Angelo Belotti,m Michele Cavo,n,o Benedetto Bruno,a,b Pellegrino Musto,p,q Mario Boccadoro,b Elena Zamagni,n,o and Francesca Gaya,b aDivision of Hematology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy bDivision of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy cDivision of Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy dMultiple Myeloma Research Foundation (MMRF), Norwalk, CT, USA eMultidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO - IRCCS, Torino, Italy fAdaptive Biotechnologies, Seattle, WA, USA gHematologic Clinic and Transplant Center, University Hospital of Central Friuli, DAME, University of Udine, Udine, Italy hDipartimento di Scienze Mediche e Chirurgiche Materno Infantili e dell’Adulto, UNIMORE, UOC Ematologia, Azienda OspedalieroUniversitaria di Modena, Modena, Italy iASST Grande Ospedale Metropolitano Niguarda, Milano, Italy jSOC Ematologia, Department of Oncology/Hematology, Azienda Ospedaliera Pugliese-Ciaccio and Department of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy kDivision of Hematology, Department of Human Pathology in Adulthood and Childhood “Gaetano Barresi”, University of Messina, Messina, Italy lUOC Ematologia, AO Cosenza, Cosenza, Italy mDepartment of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy nIRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy oDipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy pDepartment of Precision and Regenerative Medicine and Ionian Area, “Aldo Moro” University School of Medicine, Bari, Italy qHematology and Stem Cell Transplantation Unit, AOU Consorziale Policlinico, Bari, Ital

Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.

Siddiqi T, et al.
The Lancet
June 2023
Authors and Affiliates
Tanya Siddiqi, David G Maloney, Saad S Kenderian, Danielle M Brander, Kathleen Dorritie, Jacob Soumerai, Peter A Riedell, Nirav N Shah, Rajneesh Nath, Bita Fakhri, Deborah M Stephens, Shuo Ma, Tatyana Feldman, Scott R Solomon, Stephen J Schuster, Serena K Perna, Sherilyn A Tuazon, San-San Ou, Eniko Papp, Leanne Peiser, Yizhe Chen, William G Wierda Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA (T Siddiqi MD);Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA (Prof D G Maloney MD); Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA(S S Kenderian MBChB); Division of Hematologic Malignancies & Cellular Therapy, Duke University Health System, Durham, NC, USA(D M Brander MD); Division of Hematology/Oncology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA(K Dorritie MD); Department of Medicine, Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA(J Soumerai MD); Section of Hematology/Oncology, Department of Medicine, The David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL, USA(P A Riedell MD); Cancer Center, Froedtert Hospital, Medical College of Wisconsin, Milwaukee, WI, USA(N N Shah MD); Stem Cell Transplantation Cellular Therapy and Acute Leukemia, Banner MD Anderson Cancer Center, Gilbert, AZ, USA(R Nath MD); Department of Medicine, Division of Hematology and Blood and Marrow Transplant, University of California San Francisco, San Francisco, CA, USA(B Fakhri MD); Internal Medicine and Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA(D M Stephens DO); Hematology and Oncology, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA(Prof S Ma MD); T Cell Lymphoma Program, John Theurer Cancer Center at Hackensack Meridian Health, Hackensack Meridian Health School of Medicine, Hackensack, NJ, USA (T Feldman MD); Transplant and Cellular Immunotherapy Program, Northside Hospital Cancer Institute, Atlanta, GA, USA (S R Solomon MD);Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA(Prof S J Schuster MD); Bristol Myers Squibb, Princeton, NJ, USA (S K Perna MD, Y Chen PhD);Bristol Myers Squibb, Seattle, WA, USA (S A Tuazon MD, S-S Ou MS, E Papp PhD, L Peiser DPhil); Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA(Prof W G Wierda MD)

Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.

Munir T, et al.
Journal of Clinical Oncology
June 2023
Authors and Affiliates
Talha Munir, MBBS1 ; Carol Moreno, MD2; Carolyn Owen, MD3; George Follows, PhD4; Ohad Benjamini, MD5; Ann Janssens, MD, PhD6;Mark-David Levin, MD7 ; Anders Osterborg, MD, PhD8; Tadeusz Robak, MD, PhD9 ; Martin Simkovic, MD, PhD10 ; Don Stevens, MD11;Sergey Voloshin, MD, PhD12; Vladimir Vorobyev, PhD13 ; Munci Yagci, MD14; Loic Ysebaert, MD, PhD15 ; Keqin Qi, PhD16 ; Qianya Qi, PhD17;Lori Parisi, MPH17; Srimathi Srinivasan, PhD18 ; Natasha Schuier, MD19; Kurt Baeten, PhD20; Angela Howes, PhD21;Donne Bennett Caces, MD, PhD17; Carsten U. Niemann, MD, PhD22 ; and Arnon P. Kater, MD, PhD23 1 St James’s Hospital, Leeds, United Kingdom 2; Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Josep Carreras Research Leukaemia Research Institute, Barcelona, Spain3; Tom Baker Cancer Centre, Calgary, Canada 4;Addenbrookes Hospital, Cambridge, United Kingdom 5;Sheba Medical Center, Ramat Gan, Israel 6; UZ Leuven Gasthuisberg, Leuven, Belgium 7;Albert Schweitzer Hospital, Dordrecht, the Netherlands 8; Karolinska University Hospital, Stockholm, Sweden 9; Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland 10; University Hospital Hradec Kralove, Hradec Kralove, Czech Republic 11;Norton Cancer Institute, Louisville, KY 12; Russian Scientific and Research Institute of Hematology and Transfusiology, St Petersburg, Russia 13; S.P. Botkin Moscow City Clinical Hospital, Moscow, Russia 14; Gazi Universitesi Tip Fakultesi, Ankara, Turkey 15; Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France 16; Janssen Research & Development, Titusville, NJ 17; Janssen Research & Development, Raritan, NJ 18; Oncology Translational Research, Janssen Research & Development, Lower Gwynedd Township, PA 19; Janssen Research & Development, Dusseldorf, Germany ¨20; Janssen Research & Development, Beerse, Belgium 21;Janssen Research & Development, High Wycombe, United Kingdom 22; Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark 23; Amsterdam Medical Centers, University of Amsterdam, Amsterdam, the Netherlands

Teclistamab in Relapsed or Refractory Multiple Myeloma.

Moreau P, et al.
New England Journal of Medicine
June 2023
Authors and Affiliates
P. Moreau, A.L. Garfall, N.W.C.J. van de Donk, H. Nahi, J.F. San‑Miguel, A. Oriol, A.K. Nooka, T. Martin, L. Rosinol, A. Chari, L. Karlin, L. Benboubker, M.-V. Mateos, N. Bahlis, R. Popat, B. Besemer, J. Martínez‑López, S. Sidana, M. Delforge, L. Pei, D. Trancucci, R. Verona, S. Girgis, S.X.W. Lin, Y. Olyslager, M. Jaffe, C. Uhlar, T. Stephenson, R. Van Rampelbergh, A. Banerjee, J.D. Goldberg, R. Kobos, A. Krishnan, and S.Z. Usmani The Hematology Clinic, University Hospital Hôtel-Dieu, Nantes (P.M.), Service d’Hématologie Clinique, Centre Hospitalier Lyon Sud, Pierre-Bénite (L.K.), and Service d’Hématologie et Thérapie Cellulaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire, Tours (L.B.) — all in France; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.L.G.), and Janssen Research and Development, Spring House (R.V., S.G., S.X.W.L., C.U., T.S., A.B.) — both in Pennsylvania; the Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam (N.W.C.J.D.); Karolinska University Hospital at Huddinge, Stockholm (H.N.); Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Investigación Sanitaria de Navarra, Pamplona (J.F.S.-M.), Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Hospital Clínic, August Pi i Sunyer Biomedical Research Institute, University of Barcelona, Barcelona (L.R.), University Hospital of Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro del Investigación del Cáncer, CIBERONC, Salamanca (M.-V.M.), and Hematological Malignancies Clinical Research Unit, Hospital 12 de Octubre Universidad Complutense, Centro Nacional de Investigaciones Oncológicas, CIBERONC, Madrid (J.M.-L.) — all in Spain; Winship Cancer Institute, Emory University, Atlanta (A.K.N.); the University of California, San Francisco, San Francisco (T.M.), Stanford University School of Medicine, Stanford (S.S.), and City of Hope Comprehensive Cancer Center, Duarte (A.K.) — all in California; Mount Sinai School of Medicine (A.C.) and Memorial Sloan Kettering Cancer Center (S.Z.U.) — both in New York; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada (N.B.); Clinical Research Facility, National Institute for Health Research University College London Hospitals, NHS Foundation Trust, London (R.P.); the Department of Hematology, Oncology, and Immunology, University of Tübingen, Tübingen, Germany (B.B.); the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Antwerp (Y.O., R.V.R.) — both in Belgium; Janssen Research and Development, Raritan, NJ (L.P., D.T., M.J., J.D.G., R.K.); and Levine Cancer Institute– Atrium Health, Charlotte, NC (S.Z.U.).

SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study

Hill JA, et al.
May 2023
Authors and Affiliates
Joshua A Hill 1 2, Michael J Martens 3 4, Jo-Anne H Young 5, Kavita Bhavsar 3, Jianqun Kou 3, Min Chen 3, Lik Wee Lee 6, Aliyah Baluch 7, Madhav V Dhodapkar 8, Ryotaro Nakamura 9, Kristin Peyton 10, Zainab Shahid 11, Paul Armistead 12, Peter Westervelt 13, John McCarty 14, Joseph McGuirk 15, Mehdi Hamadani 16, Susan DeWolf 11, Kinga Hosszu 11, Elad Sharon 17, Ashley Spahn 18, Amir A Toor 14, Stephanie Waldvogel 18, Lee M Greenberger 19, Jeffery J Auletta 18 20, Mary M Horowitz 3, Marcie L Riches 3, Miguel-Angel Perales 11 21; 1 Vaccine and Infectious Disease, Fred Hutchinson Cancer Center, Seattle, WA, USA. 2 Department of Medicine, University of Washington, Seattle, WA, USA. 3 Center for International Blood and Marrow Transplantation Research, Medical College of Wisconsin, Milwaukee, WI, USA. 4 Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, USA. 5 University of Minnesota, Minneapolis, MN, USA. 6 Adaptive Biotechnologies Corp, Seattle, WA, USA. 7 H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. 8 Emory University - School of Medicine, Atlanta, GA, USA. 9 City of Hope, Duarte, CA, USA. 10 The Emmes Company, Rockville, MD, USA. 11 Memorial Sloan Kettering Cancer Center, New York, NY, USA. 12 University of North Carolina Medical Center, Chapel Hill, NC, USA. 13 Barnes-Jewish Hospital, Washington University, St. Louis, MO, USA. 14 Virginia Commonwealth University, Richmond, VA, USA. 15 University of Kansas, Lawrence, KS, USA. 16 Medical College of Wisconsin, Milwaukee, WI, USA. 17 National Cancer Institute, Bethesda, MD, USA. 18 National Marrow Donor Program/Center for International Blood and Marrow Transplant Research, Minneapolis, MN, USA. 19 The Leukemia and Lymphoma Society, Rye Brook, New York, NY, USA. 20 Nationwide Children's Hospital, Columbus, OH, USA. 21 Weil Cornell Medical College, New York, NY, USA.

Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer

Rojas LA, et al.
May 2023
Authors and Affiliates
Luis A. Rojas #1,2, Zachary Sethna #1,2, Kevin C. Soares 2,3, Cristina Olcese 2, Nan Pang 2, Erin Patterson 2, Jayon Lihm 4, Nicholas Ceglia 4, Pablo Guasp 1,2, Alexander Chu 4, Rebecca Yu 1,2, Adrienne Kaya Chandra 1,2, Theresa Waters 1,2, Jennifer Ruan 1,2, Masataka Amisaki 1,2, Abderezak Zebboudj 1,2, Zagaa Odgerel 1,2, George Payne 1,2, Evelyna Derhovanessian 5, Felicitas Müller 5, Ina Rhee 6, Mahesh Yadav 6, Anton Dobrin 7,8, Michel Sadelain 7,8, Marta Łuksza 9, Noah Cohen 10, Laura Tang 11, Olca Basturk 11, Mithat Gönen 12, Seth Katz 13, Richard Kinh Do13, Andrew S. Epstein 14, Parisa Momtaz 14, Wungki Park 3,14, Ryan Sugarman 14, Anna M. Varghese 14, Elizabeth Won 14, Avni Desai 14, Alice C. Wei 2,3, Michael I. D’Angelica 2,3, T. Peter Kingham 2,3, Ira Mellman 6, Taha Merghoub 15, Jedd D. Wolchok 15, Ugur Sahin 5, Özlem Türeci 5,16, Benjamin D. Greenbaum (corresponding author) 4,17, William R. Jarnagin 2,3, Jeffrey Drebin 2,3, Eileen M. O’Reilly 3,14, and Vinod P. Balachandran (corresponding author) 1,2,3; 1 Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY USA. 2 Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY USA. 3 David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY USA. 4 Computational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY USA. 5 BioNTech, Mainz, Germany. 6 Genentech, San Francisco, CA USA. 7 Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY USA. 8 Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY USA. 9 Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY USA. 10 Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, NY USA. 11 Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA. 12 Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY USA. 13 Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY USA. 14 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY USA. 15 Meyer Cancer Center, Weill Cornell Medicine, Weill Cornell Medical College, New York, NY USA. 16 HI-TRON, Helmholtz Institute for Translational Oncology, Mainz, Germany. 17 Physiology, Biophysics and Systems Biology, Weill Cornell Medicine, Weill Cornell Medical College, New York, NY USA.

TCR sequencing and cloning methods for repertoire analysis and isolation of tumor-reactive TCRs

Genolet R, et al.
May 2023
Authors and Affiliates
Raphael Genolet 1,2,4,∗ Sara Bobisse 1,2, Johanna Chiffelle 1,2, Marion Arnaud 1,2, Rémy Petremand 1,2, Lise Queiroz 1,2, Alexandra Michel 1,2, Patrick Reichenbach 1, Julien Cesbron 1,2 Aymeric Auger 1,2, Petra Baumgaertner 1,2, Philippe Guillaume 1,2, Julien Schmidt 1,2, Melita Irving 1, Lana E. Kandalaft1,2, Daniel E. Speiser 1, George Coukos 1,3,∗∗ and Alexandre Harari 1,3,∗∗∗; 1 Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne and Lausanne University Hospital, Lausanne, Switzerland. 2 Center of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland. Raphael Genolet: hc.vuhc@teloneg.leahpar; George Coukos: hc.vuhc@sokuoc.egroeg; Alexandre Harari: hc.vuhc@irarah.erdnaxela
Previous Next